Natural Products Useful in Respiratory Disorders: Focus on Side-Effect Neutralizing Combinations

Khan, Arif‐ullah; Gilani, Anwarul Hassan

doi:10.1002/ptr.5380

Cited by 14 publications

(9 citation statements)

References 100 publications

(74 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Besides, combined pharmacological activities of medicinal plants may exert adverse effect. [ 31 ] Consequently, the safety of YPFF needs to be further investigated.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant treatment with Yupingfeng formula for primary nephrotic syndrome in children

Shi

Zhong²,

Ding³

2018

Medicine

View full text Add to dashboard Cite

show abstract

“…Besides, combined pharmacological activities of medicinal plants may exert adverse effect. [ 31 ] Consequently, the safety of YPFF needs to be further investigated.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant treatment with Yupingfeng formula for primary nephrotic syndrome in children

Shi

Zhong²,

Ding³

2018

Medicine

View full text Add to dashboard Cite

show abstract

“…We have reported co-existence of PDEIs component(s) with Ca ++ antagonist(s) in some medicinal plants [65–68]. As, combination of PDEIs and Ca ++ antagonists have synergistic spasmolytic interaction in smooth muscles (more effective in respiratory system) and opposing/side effects neutralizing effects in heart [69], hence might making the plant more efficacious to relax airways, compared to cardiac muscles.…”

Section: Discussionmentioning

confidence: 99%

Antispasmodic, bronchodilator, vasorelaxant and cardiosuppressant effects of Buxus papillosa

Khan

Ali

Gilani

et al. 2017

BMC Complement Altern Med

Self Cite

View full text Add to dashboard Cite

BackgroundThe present research was carried out to investigate pharmacological properties of Buxus papillosa C.K. Schneid. (Buxaceae).Methods Buxus papillosa extracts of leaves (BpL), stem (BpS), roots (BpR) and BpL fractions: hexane (BpL-H), aqueous (BpL-A) also plant constituent, cyclomicrobuxine effect were studied in jejunum, atria, aorta and tracheal preparations from rabbit and guine-peg.ResultsCa++ antagonistic effect of BpS, BpR, BpL-H, BpL-A and cyclomicrobuxine were conclusively suggested, when spontaneous contractions of rabbit jejunal preparation was relaxed along with subsequent relaxation of potassium chloride (80 mM) induced contractions. Ca++ antagonistic effect was further confirmed, when a prominent right shift like that of verapamil was observed in Ca++ concentration-response curves, drawn in a tissue pretreated with BpL (0.3–1.0 mg/mL). In rabbit tracheal tissues BpL, BpS, BpR, BpL-H and BpL-A produced a prominent relaxation in contractions induced by potassium chloride (80 mM) and carbachol (1 μm). When tested in rabbit aortic rings, BpL, BpS, BpR, BpL-H and BpL-A showed concentration-dependent (0.1–3.0 mg/mL) vasorelaxant effect against phenylephrine (1 μM) and high K+-induced contractions. In isolated guinea-pig right atria, BpL, BpS, BpR, BpL-H and BpL-A suppressed atrial force of spontaneous contractions, with BpL-A being most potent.ConclusionsOur results reveal that Buxus papillosa possesses gut, airways and cardiovascular inhibitory actions.

show abstract

“…However, attentions should be given to the adverse events of YPFF because of only three trials (Cai and Cai, ; Ma and Liu, ; Zhang, ) reported the safety as outcome. Importantly, combinations of pharmacological activities in medicinal plants might exert adverse effect‐neutralizing/synergistic potential (Khan and Gilani, ). Therefore, the safety of YPFF needs to be further investigated.…”

Section: Discussionmentioning

confidence: 99%

Adjuvant Treatment with Yupingfeng Formula for Recurrent Respiratory Tract Infections in Children: A Meta-analysis of Randomized Controlled Trials

Song

Hou

et al. 2016

Phytother. Res.

View full text Add to dashboard Cite

This meta-analysis aimed to evaluate the immunomodulating function of Yupingfeng Formula (YPFF) in children with recurrent respiratory tract infections (RRTIs). The PubMed, EMBASE, Cochrane Library, CNKI and WanFang databases were searched for randomized controlled trials comparing with and without YPFF for RRTIs in children. Twelve trials with 1236 patients were identified. Adjuvant treatment with YPFF significantly increased serum levels of IgA (weighted mean difference [WMD] 0.33 mg/mL; 95% confidence interval [CI] 0.20 to 0.45), IgG (WMD 1.36 mg/mL; 95% CI 1.06 to 1.65), IgM (WMD 0.16 mg/mL; 95% CI 0.02 to 0.31), and CD3(+) T-lymphocytes (WMD 10.16%; 95% CI 4.62 to 15.69) but not CD4(+) T-lymphocytes (WMD 3.16%; 95% CI -0.27 to 6.59) and CD8(+) T-lymphocytes (WMD -0.84%; 95% CI -2.50 to 0.81). YPFF also reduced the frequency of RRTIs (WMD -3.80 times; 95% CI -4.86 to -2.74) and increased total effective rates of symptom improvement (risk ratio: 1.44; 95% CI 1.19 to 1.75). Adjuvant treatment with YPFF could improve total clinical effective rate and decrease the frequency of respiratory tract infections in children with RRTIs. The beneficial effects of YPFF may be correlated to its immunomodulating action. More well-designed trials with larger sample sizes are needed to evaluate its efficacy and safety. Copyright © 2016 John Wiley& Sons, Ltd.

show abstract

Natural Products Useful in Respiratory Disorders: Focus on Side-Effect Neutralizing Combinations

Cited by 14 publications

References 100 publications

Adjuvant treatment with Yupingfeng formula for primary nephrotic syndrome in children

Adjuvant treatment with Yupingfeng formula for primary nephrotic syndrome in children

Antispasmodic, bronchodilator, vasorelaxant and cardiosuppressant effects of Buxus papillosa

Adjuvant Treatment with Yupingfeng Formula for Recurrent Respiratory Tract Infections in Children: A Meta-analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About